Trial record 1 of 1 for:
NCT00168441
A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00168441 |
Recruitment Status :
Completed
First Posted : September 15, 2005
Last Update Posted : May 30, 2011
|
Sponsor:
Allergan
Information provided by:
Allergan
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
4-month study including a 30-day baseline phase
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postherpetic Neuralgia | Drug: Botulinum Toxin Type A | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 117 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Study Start Date : | June 2004 |
Actual Primary Completion Date : | June 2005 |
Actual Study Completion Date : | June 2005 |
Resource links provided by the National Library of Medicine

Primary Outcome Measures :
- Pain score
Secondary Outcome Measures :
- Various Quality of Life questionnaires
- Reduction in area of pain/allodynia
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.
Exclusion Criteria:
- Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.
No Contacts or Locations Provided
Responsible Party: | Therapeutic Area Head, Allergan, Inc |
ClinicalTrials.gov Identifier: | NCT00168441 |
Other Study ID Numbers: |
191622-066 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | May 30, 2011 |
Last Verified: | May 2011 |
Additional relevant MeSH terms:
Neuralgia Neuralgia, Postherpetic Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Pain Neurologic Manifestations Botulinum Toxins Botulinum Toxins, Type A |
abobotulinumtoxinA Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |